About Us
Careers
Partner with us
Forgot password?
Sign in
Login
Login
Email
Password
Forgot your password?
Join VuMedi
Select specialty
Your main specialty
Adult & Family Medicine
Allergy, Asthma, Immunology
Anesthesiology
Cardiovascular
Dental
Dermatology
Emergency Medicine
Endocrinology
Gastroenterology & Hepatology
General Surgery
Hematology & Oncology
Infectious Disease
Medical Genetics
Nephrology
Neurology
Neurosurgery
Obstetrics/Gynecology
Ophthalmology
Oral Maxillofacial
Orthopaedics
Otolaryngology
Pathology
Pediatrics
Physical Medicine & Rehab
Plastic Surgery
Podiatry
Preventive Medicine
Psychiatry
Pulmonology
Radiation Oncology
Radiology
Rheumatology
Urology
First name
Last name
Email
Choose Password
Memorial Sloan Kettering Cancer Center
https://www.mskcc.org/healthcare-professionals
Refer a Patient to MSKCC:
mskcc.org/refer
COVID-19
Myeloma
Leukemia
Lymphoma
Hematologic Transplantation and Malignancies
Breast
Lung
Gastrointestinal
Genitourinary
Gynecologic
Skin
Head and Neck
Brain
General Oncology
Palliative Care
Events
MPN
Playback speed
0.5x
0.75x
1x (Normal)
1.25x
1.5x
1.75x
2x
10 seconds
New Kinase Inhibitors for CML: Asciminib, PF-114, & HQP1351
By
Society of Hematologic Oncology Seventh Annual Meeting (SOHO 2019)
FEATURING
Michael J. Mauro
By
Society of Hematologic Oncology Seventh Annual Meeting (SOHO 2019)
FEATURING
Michael J. Mauro
23 views
October 16, 2019
0 Comments
Login to view comments.
Click here to Login
Featured Video
15:14
Icahn School of Medicine at Mount Sinai
Safety Profile of Ruxolitinib in Patients With MF
Feat.
D. Tremblay
Featured Video
13:04
Winship Cancer Institute - Emory University
Treatment-Related Quality of Life in MF
Feat.
A. Hunter
Leukemia
15:23
SOHO 2023 Eleventh Annual Meeting
SOHO 2023: Updates on the Role of SCT in ALL in the Era of CAR-T
Feat.
J. Park
13:15
SOHO 2023 Eleventh Annual Meeting
SOHO 2023 Menin Inhibition for KMT2A-Rearranged ALL
Feat.
E. Stein
30:21
International CML Foundation
ASH 2022 Highlights on CML: Clinical Overview From iCMLf
Feat.
M. Mauro
04:55
ASH 2022 Conference Coverage
ASH 2022 Initial Results From SELECT-AML-1: a Phase 2 Study of Tamib…
Feat.
E. Stein
04:22
EHA 2022 Conference Coverage
EHA 2022 Tamibarotene in Combination With Ven & Aza in Previousl…
Feat.
E. Stein
54:58
PleXus Communications
Expert Perspectives on Treating High-Risk and R/R AML
Feat.
E. Stein
04:36
ecancer
Safety & Efficacy of Asciminib for Heavily Pretreated Patients W…
Feat.
M. Mauro
05:49
ASH 2021 Conference Coverage on VuMedi
ASH 2021 Update on the Safety & Efficacy of Menin Inhibition in …
Feat.
E. Stein
16:42
University of Miami's 2nd Biennial Miami Leukemia Symposium
IDH Inhibitors in Myeloid Malignancies: What Are the Mechanisms of R…
Feat.
E. Stein
06:19
Cleveland Clinic's 20th Annual ASH Review
2019 ASH Review of Frontline CLL: Is There a Role for FCR in 2020 an…
Feat.
A. Mato
07:59
Cleveland Clinic's 20th Annual ASH Review
2019 ASH Review of Frontline CLL: Can We Improve CIT by Adding a Nov…
Feat.
A. Mato
05:08
Cleveland Clinic's 20th Annual ASH Review
2019 ASH Review on Combinations or Sequences of Targeted Agents in C…
Feat.
A. Mato
04:52
Cleveland Clinic's 20th Annual ASH Review
2019 ASH Review on Venetoclax in the R/R CLL: With Additional Follow…
Feat.
A. Mato
08:21
Cleveland Clinic's 20th Annual ASH Review
2019 ASH Review on Overcoming BTKi Resistance in CLL: Era of Non-Cov…
Feat.
A. Mato
15:19
Society of Hematologic Oncology Seventh Annual Meeting (SOHO 2019)
29 y/o Male w/ CML: Allograft vs. 3rd Line Therapy - Transplant Is A…
Feat.
M. Mauro
15:59
Society of Hematologic Oncology Seventh Annual Meeting (SOHO 2019)
New Kinase Inhibitors for CML: Asciminib, PF-114, & HQP1351
Feat.
M. Mauro
27:00
Indy Hematology Review
Acute Myeloid Leukemia - Overview of Available Novel Agents with Uni…
Feat.
M. Tallman
07:46
Society of Hematologic Oncology Sixth Annual Meeting (SOHO 2018)
Oral Abstract CML-044: Treatment-Free Remission (TFR) in Patients wi…
Feat.
M. Mauro
17:58
Memorial Sloan Kettering Cancer Center
Front-line Strategies in Ph-negative ALL
Feat.
M. Geyer
13:41
Memorial Sloan Kettering Cancer Center
Updates and Challenges in the Management of Chronic Myeloid Leukemia…
Feat.
M. Mauro
17:13
Memorial Sloan Kettering Cancer Center
Multi-drug Resistant and Intolerant CML: What to Do?
Feat.
M. Mauro
08:42
Memorial Sloan Kettering Cancer Center
IDH Inhibitors in AML
Feat.
E. Stein